Skip to main content
SpringerLink
Log in

Pneumococcal vaccines: search for an optimal agent

  • News item
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

REFERENCE

  1. Patel R, Stoykova B, Lloyd AC, Willingham J, Hollingsworth R.A Comparison of the Cost-effectiveness of the 13-Valent (Pcv13) and 10-Valent Pneumococcal Conjugate Vaccines in the Uk. 12th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research: abstr. PIN57, 24 Oct 2009. Available from: URL: http://www.ispor.org/Events/Index.aspx?eventId=30

  2. Claes C, Mittendorf T, Kuchenbecker U, Rose M, Reinert RR.Cost-effectiveness of Switching Strategies From a 7-Valent to a 13-Valent Pneumococcal Conjugate Vaccine. 12th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research: abstr. PIN42, 24 Oct 2009. Available from: URL: http://www.ispor.org/Events/Index.aspx?eventId=30

  3. Whillans F, KWAN H, Strutton DR, Earnshaw SR, Farkouh R.Cost-effectiveness of 13-Valent and 10-Valent Pneumococcal Conjugate Vaccination Relative to 7-Valent Pneumococcal Conjugate Vaccination in Canada. 12th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research: abstr. PIN43, 24 Oct 2009. Available from: URL: http://www.ispor.org/Events/Index.aspx?eventId=30

  4. Ismaila AS, Chen YC, Standaert BA, PereiraJA, Robson RC.Potential health and economic impact of new pneumococcal vaccines in canada: a Markov modelling approach. 12th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research: abstr. PIN33, 24 Oct 2009. Available from: URL: http://www.ispor.org/Events/Index.aspx?eventId=30

  5. Knoll S, Jochum D, Talbird SE.Cost-utility analysis of Pneumococcal conjugate vaccines in Germany. 12th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research: abstr. PIN63, 24 Oct 2009. Available from: URL: http://www.ispor.org/Events/Index.aspx?eventId=30

  6. Kawalec P, Holko P, Dziurda D, Glogowski C.Economic Assessment of Mass Vaccination with Pneumococcal Non-typeable Haemophilus Influenzae Protein D Conjugate Vaccine (Phid-cv) in Poland. 12th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research: abstr. PIN34, 24 Oct 2009. Available from: URL: http://www.ispor.org/Events/Index.aspx?eventId=30

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pneumococcal vaccines: search for an optimal agent. Pharmacoecon. Outcomes News 591, 3–4 (2009). https://doi.org/10.2165/00151234-200905910-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00151234-200905910-00003

Keywords

Search

Navigation